Search Results
Your search for ,jCo matches 1780 pages
Showing 1301 - 1350No Improvement in Undetectable PSA Rate With Cixutumumab Plus Androgen-Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer
In a randomized phase II trial (SWOG S0925) reported in the Journal of Clinical Oncology, Yu et al found that the addition of cixutumumab to androgen-deprivation therapy did not significantly increase the rate of undetectable prostate-specific antigen (PSA) in patients with newly diagnosed...
Single-Center Experience Indicates Relatively Good Prognosis After Allogeneic Stem Cell Transplantation Failure in CLL
In a retrospective single-center study reported in Journal of Clinical Oncology, Rozovski and colleagues found that chronic lymphocytic leukemia (CLL) patients with disease progression after allogeneic stem cell transplantation had a relatively good prognosis, with apparent benefit of salvage...
One-Third of Breast Cancer Patients Concerned About Genetic Risk
A new study from the University of Michigan Comprehensive Cancer Center found that many women diagnosed with breast cancer are concerned about the genetic risk of developing other cancers themselves, or of a loved one developing cancer. These findings were published by Jagsi et al in the Journal of ...
Glembatumumab Vedotin Appears Active in Heavily Treated Advanced Glycoprotein NMB–Overexpressing Breast Cancer and Triple-Negative Disease
In the randomized phase II EMERGE study reported in the Journal of Clinical Oncology, Yardley et al found that the anti–glycoprotein NMB (gpNMB) antibody-drug conjugate glembatumumab vedotin may improve response rate over alternative chemotherapy in patients with advanced refractory breast...
Circulating Tumor Cell Count and LDH Level as Patient-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
In an analysis reported in the Journal of Clinical Oncology, Scher et al found that circulating tumor cell count and LDH level served as an individual-level surrogate for survival among patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate (Zytiga) plus...
Platinum Monotherapy Particularly Active in BRCA1/2-Mutant Metastatic Triple-Negative Breast Cancer
In the phase II TBCRC009 trial reported in the Journal of Clinical Oncology, Isakoff et al found that platinum monotherapy was active in treatment of metastatic triple-negative breast cancer, particularly in cases with BRCA1/2 mutation, and that an assay of genomic instability characteristic of...
Neoadjuvant Iniparib Plus Gemcitabine-Carboplatin Is Active in Early Triple-Negative and BRCA1/2-Mutant Breast Cancer
In the phase II PrECOG 0105 study reported in the Journal of Clinical Oncology, Telli et al found that neoadjuvant iniparib plus gemcitabine-carboplatin was active in early-stage triple-negative and BRCA1/2-mutant breast cancer. Higher score on a homologous recombination deficiency–loss of...
Complete Regression of Metastatic Cervical Cancer Is Observed After Treatment With HPV-Targeted Tumor-Infiltrating T Cells
As reported in the Journal of Clinical Oncology, Stevanovíc et al observed complete regression of metastatic cervical tumors in two patients following a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells. In the protocol, nine patients with metastatic cervical ...
Durable Responses With Nivolumab in Previously Treated Advanced Renal Cell Carcinoma
In a phase I cohort-expansion study reported in the Journal of Clinical Oncology, McDermott et al found that nivolumab (Opdivo) produced durable responses in patients with previously treated advanced renal cell carcinoma. Responses continued after nivolumab discontinuation in some patients. Study...
NPM1-Positive/FLT3-ITD–Negative Genotype Not Associated With Significantly Better Prognosis in Older AML Patients
In a study reported in the Journal of Clinical Oncology, Ostronoff et al found that the presence of the NPM1-positive/FLT3-internal tandem duplication (ITD)–negative genotype—which is recognized as a marker of better prognosis in younger patients with acute myeloid leukemia—was...
Worse Outcomes With Lapatinib vs Trastuzumab Plus Taxane in Advanced HER2-Positive Breast Cancer
In the phase III National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA.31 trial, first-line treatment with lapatinib (Tykerb) vs trastuzumab (Herceptin) combined with a taxane was associated with poorer progression-free survival and greater toxicity in patients with advanced...
Analysis Indicates Poorer Progression-Free and Overall Survival With Lower Baseline Vitamin D Levels in Follicular Lymphoma Patients
In an analysis reported in the Journal of Clinical Oncology, Kelly et al found that low baseline serum vitamin D levels are associated with poorer progression-free and overall survival in patients with previously untreated follicular lymphoma. Study Details The study involved analysis of data...
Persistence of HER2-Specific CAR T Cells in HER2‑Positive Sarcoma
In a phase I/II study reported in Journal of Clinical Oncology, Ahmed et al found that infusion of T cells expressing HER2-specific chimeric antigen receptor (CAR) with a CD28.ζ signaling domain (HER2-CAR T cells) could produce persistent CAR T cell levels for ≥ 6 weeks in patients with...
Five-Year Analysis Indicates Potential for Long‑Term Survival With Ipilimumab Plus Dacarbazine in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Maio et al found a 5-year survival rate of 18% among treatment-naive patients receiving ipilimumab (Yervoy) plus dacarbazine in a phase III trial. The findings support other data indicating long-term survival in some patients receiving...
Translocation t(11;14) Associated With Poorer Outcome in Bortezomib-Treated Newly Diagnosed Amyloid Light-Chain Amyloidosis
In a single-institution study reported in the Journal of Clinical Oncology, Bochtler et al found that presence of the t(11;14) translocation on interphase fluorescence in situ hybridization (iFISH) was associated with poorer hematologic event-free and overall survival in patients receiving...
No Differences in Patient-Reported Outcomes or Resource Use With Early vs Delayed Initiation of Palliative Care Intervention
In the ENABLE III study reported in the Journal of Clinical Oncology, Bakitas et al found that early vs delayed initiation of a palliative care intervention did not result in improved patient-reported outcomes or resource use. Early initiation was associated with better 1-year survival. Study...
Reduced Family Caregiver Depression With Early vs Delayed Palliative Care Intervention for Caregivers
In the ENABLE III study reported in the Journal of Clinical Oncology, Dionne-Odom et al found that early vs delayed use of a palliative care intervention for family caregivers of patients with advanced cancer reduced caregiver depression scores and caregiver stress burden. No differences in...
Gonadotropin-Releasing Hormone Agonist Treatment and Orchiectomy Linked to Increased Risk of Cardiovascular Disease in Men With Prostate Cancer
In a study of Swedish men with prostate cancer reported in the Journal of Clinical Oncology, O’Farrell et al found that use of gonadotropin-releasing hormone (GnRH) agonists and orchiectomy were associated with a significantly increased risk of incident cardiovascular disease. In patients...
Intraperitoneal Chemotherapy Associated With Long-Term Survival Advantage Over Intravenous Chemotherapy in Advanced Ovarian Cancer
In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Tewari et al found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous chemotherapy in women with advanced ovarian cancer. Study Details The...
Insufficient Awareness of Breast Density and Its Impact on Breast Cancer Detection and Risk
In a study reported in the Journal of Clinical Oncology, Rhodes et al found that only about half of screening-age women had awareness of breast density and adequate knowledge of its impact on breast cancer detection and risk. Breast density is an important factor contributing to false-negative...
Low Nadir Testosterone in First Year of Hormone Therapy Linked to Improved Cause-Specific Survival and Delay of Hormone Resistance in Prostate Cancer
In an analysis from the PR-7 trial reported in the Journal of Clinical Oncology, Klotz et al found that in men with prostate cancer with biochemical failure after radiotherapy with or without surgery, a nadir serum testosterone level ≤ 0.7 nmol/L during the first year of continuous...
Elevated C-Reactive Protein Associated With Poorer Outcome in Melanoma
In a study reported in the Journal of Clinical Oncology, Fang et al found that an elevated C-reactive protein level was associated with poorer overall and melanoma-specific survival in patients with melanoma and that sequential increases in C-reactive protein were associated with an increased risk...
No Improvement in Complete Remission Rate With Cytarabine Plus Amonafide L-Malate vs Daunorubicin in Secondary AML
In a phase III trial reported in the Journal of Clinical Oncology, Stone et al found that the combination of cytarabine and amonafide L-malate, a DNA intercalator and non–ATP-dependent topoisomerase II inhibitor, did not improve complete remission rate compared with cytarabine plus...
Marked Increase in Fracture Risk in Patients Receiving Hematopoietic Stem Cell Transplantation
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Pundole et al found that patients undergoing hematopoietic stem cell transplantation are at increased risk of bone fracture later in life, with risk being particularly elevated in women and men aged 45 to 64...
No Difference in Event-Free Survival With Stem Cell Transplantation Using Matched Unrelated vs Sibling Donor Grafts in Children With ALL
In a European trial (Berlin-Frankfurt-Muenster study group trial ALL-SCT-BFM 2003) reported in the Journal of Clinical Oncology, Peters et al found no difference in event-free survival with stem cell transplantation using matched unrelated vs sibling donors in pediatric patients with high-risk...
European Retrospective Study Shows Activity of Crizotinib in Advanced Lung Adenocarcinoma With ROS1 Rearrangement
In a retrospective study in the European EUROS1 cohort reported in the Journal of Clinical Oncology, Mazières found that crizotinib (Xalkori) treatment was associated with an 80% response rate in patients with stage IV lung adenocarcinoma with ROS1 rearrangement. Study Details The study...
Findings in Pooled Analysis of Long-Term Survival With Ipilimumab in Advanced Melanoma
In a pooled analysis reported in the Journal of Clinical Oncology, Schadendorf et al found 3-year overall survival rates of 26% and 20% in treatment-naive and previously treated patients receiving ipilimumab (Yervoy)-based treatment for unresectable or metastatic melanoma. A survival curve plateau...
Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma Defined by BRAF Mutation and CDKN2A Deletion
In a study reported in the Journal of Clinical Oncology, Mistry et al found that presence of BRAF V600E mutation and CDKN2A deletion defined a clinically distinct subtype of pediatric secondary high-grade glioma. BRAF V600E mutation was associated with a prolonged time to transformation. Study...
Reduced Mammography Rates 3 Years After 2009 U.S. Preventive Services Task Force Guidelines Changes
In a study reported in the Journal of Clinical Oncology, Wharam et al found that estimated mammography rates were lower than predicted in white, Hispanic, and Asian women since the U.S. Preventive Services Task Force (USPSTF) changed its screening recommendations in November 2009. The guidelines...
Outcomes of Phase II Basket Trial of Molecular Profiling and Targeted Therapy in Advanced Thoracic Malignancies
In a basket trial (CUSTOM) reported in the Journal of Clinical Oncology, Lopez-Chavez et al performed molecular profiling of tumors in patients with advanced non–small cell lung cancer (NSCLC), small cell lung cancer, or thymic malignancies and assigned those in any of five actionable...
Maintenance Sunitinib Improves Progression-Free Survival in Phase II Trial in Untreated Extensive-Stage Small Cell Lung Cancer
In the randomized phase II Cancer and Leukemia Group B (CALGB) 30504/Alliance trial reported in the Journal of Clinical Oncology, Ready et al found that sunitinib (Sutent) vs placebo maintenance following chemotherapy improved progression-free survival in patients with previously untreated...
MRI Screening More Sensitive Than Mammography and Ultrasound for Familial Breast Cancer Irrespective of Age, Mutation Status, or Breast Density
In a single-center study reported in the Journal of Clinical Oncology, Riedl et al found that screening with magnetic resonance imaging (MRI) had greater sensitivity for detection of breast cancer in high-risk women vs mammography or ultrasound irrespective of age, mutation status, or breast...
No Benefit of Adding Bevacizumab to First-Line Gemcitabine-Docetaxel in Metastatic Uterine Leiomyosarcoma
In a phase III NRG Oncology/Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Hensley et al found no benefit of adding bevacizumab (Avastin) to first-line gemcitabine-docetaxel in patients with metastatic uterine leiomyosarcoma. Study Details In this...
Greater Guideline Adherence, Better Survival, Absence of Racial Survival Disparity Among Colorectal Cancer Patients in Integrated Health-Care System
In a retrospective analysis reported in the Journal of Clinical Oncology, Rhoads et al found that treatment of colorectal cancer patients in an integrated health-care system was associated with greater compliance with National Comprehensive Cancer Network (NCCN) guidelines, better survival, and no...
Addition of Orteronel to Prednisone in Metastatic Castration-Resistant Prostate Cancer Does Not Meet Overall Survival Endpoint in Phase III Trial
In a phase III trial (ELM-PC 5) reported in the Journal of Clinical Oncology, Fizazi et al found that the addition of the 17,20-lyase inhibitor orteronel to prednisone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel therapy resulted in an overall...
Complex Surgery Does Not Independently Predict Outcome in Advanced Ovarian Cancer
In an analysis in the Gynecologic Oncology Group (GOG 182) trial population reported in the Journal of Clinical Oncology, Horowitz et al found that more complex surgery was not an independent predictor of progression-free or overall survival among patients with advanced epithelial ovarian or...
Immunologic Factors Predict Pathologic Complete Response to Neoadjuvant Therapy With or Without Carboplatin in Breast Cancer
In a study reported in the Journal of Clinical Oncology, Denkert et al found that increased tumor-infiltrating lymphocytes and the presence of lymphocyte-predominant breast cancer were associated with increased rates of pathologic complete response in patients receiving neoadjuvant...
Acceptable Cardiac Safety of Ado-Trastuzumab Emtansine After Anthracycline-Based Chemotherapy in Early-Stage HER2-Positive Breast Cancer
In a study reported in the Journal of Clinical Oncology, Krop et al found that ado-trastuzumab emtansine (Kadcyla) had an acceptable cardiac safety profile when used after anthracycline-based (neo)adjuvant therapy in women with early-stage HER2-positive breast cancer. Study Details In the study,...
Lower Household Net Worth and Black Race Associated With Nonadherence to Hormonal Therapy for Early-Stage Breast Cancer
In a study reported in the Journal of Clinical Oncology, Hershman et al found that nonadherence to adjuvant hormonal therapy for early-stage breast cancer was more common among black women and patients with lower household net worth, with the latter factor partly accounting for the racial...
Oral Bisphosphonate Use Reduces Risk of Postmenopausal Endometrial Cancer
Bisphosphonate use for treatment or prevention of osteoporosis in postmenopausal women has been associated with a reduced risk of breast cancer, including in a study in the Women’s Health Initiative (WHI) population. In a WHI study reported in the Journal of Clinical Oncology, Newcomb et al...
Cost-Effectiveness Analysis of First- and Second-Line Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer
In a U.S.-based cost-effectiveness analysis reported in the Journal of Clinical Oncology, Goldstein et al found high costs per quality-adjusted life-year with the addition of bevacizumab (Avastin) to chemotherapy in first- and second-line treatment of metastatic colorectal cancer. Study Details...
Inconclusive Outcome for Lapatinib vs Trastuzumab Plus Capecitabine in Preventing CNS Metastases as First Relapse Site in HER2-Positive Breast Cancer
In the phase III CEREBEL study reported in the Journal of Clinical Oncology, Pivot et al compared lapatinib (Tykerb)-capecitabine vs trastuzumab (Herceptin)-capecitabine in the prevention of central nervous system (CNS) metastases as first relapse site in patients with metastatic HER2-positive...
New Model Provides Improved Prediction of Breast Cancer Risk in African American Women
Breast cancer risk prediction models have underestimated the risk for African American women, a factor that has contributed to lower rates of recruitment to prevention trials in this population. In a study reported in the Journal of Clinical Oncology, Boggs et al developed a risk model, derived...
Final 8-Year Analysis of Intergroup Trial Shows Survival Benefit With Addition of Radiotherapy to Androgen-Deprivation Therapy in Prostate Cancer
In the final prespecified analysis of an Intergroup trial (NCIC Clinical Trials Group PR.3/Medical Research Council PR07/Intergroup T94-0110) reported in the Journal of Clinical Oncology, Mason et al found that overall survival and cancer-specific survival at 8 years were significantly greater with ...
Japanese Study Indicates Death at Home Is Better for Terminally Ill Cancer Patients
In a Japanese study reported in the Journal of Clinical Oncology, Kinoshita et al found that death at home vs palliative care units or hospitals was better for terminally ill cancer patients and was not associated with an increased caregiver burden. Study Details The study included two...
No Progression-Free Survival Benefit of Adding Bevacizumab to Endocrine Therapy in First-Line Treatment for Advanced Breast Cancer
In a Spanish-German phase III LEA trial reported in the Journal of Clinical Oncology, Martín et al found that adding bevacizumab (Avastin) to endocrine therapy with letrozole or fulvestrant (Faslodex) in the first-line treatment of postmenopausal women with advanced breast cancer did not...
Axillary Ultrasound After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer Could Reduce Sentinel Lymph Node False-Negative Rate
In the American College of Surgeons Oncology Group Z1071 trial, sentinel lymph node surgery after neoadjuvant chemotherapy was associated with a 12.6% false-negative rate in breast cancer patients with cN1 disease. In an analysis of axillary ultrasound findings in the trial, a secondary endpoint,...
Improved TNM Prediction of Survival in HPV‑Related Oropharyngeal Carcinoma
In a study reported in the Journal of Clinical Oncology, Huang et al showed that recursive portioning analysis (RPA) could be used to provide TNM stage grouping with improved prediction of survival in patients with human papillomavirus (HPV)-related nonmetastatic oropharyngeal carcinoma. ...
FDA Analysis Explores Relationship Between Response Rate and Survival at Trial and Patient Levels in Advanced NSCLC Studies
In a U.S. Food and Drug Administration (FDA) analysis of randomized trials in advanced non–small cell lung cancer (NSCLC) reported in the Journal of Clinical Oncology, Blumenthal et al found a strong correlation between response rate and progression-free survival at the trial level and a...
Adding Cetuximab to First-Line FOLFIRI Does Not Benefit Metastatic Colorectal Cancer Patients With RAS Mutations
The phase III CRYSTAL trial showed that the addition of cetuximab (Erbitux) to first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) significantly improved overall survival, progression-free survival, and objective response rates in patients with KRAS codon 12/13 (exon 2) wild-type...
